Daewoong's Diabetes Drug Enblo Eyes Heart, Kidney Indications in Global Push

Daewoong Pharmaceutical (069620.KQ) is accelerating large-scale clinical trials for its novel drug Enblo to prove cardiovascular and renal protective effects, expanding beyond its original diabetes treatment scope to target the global market. The move marks a full-scale push to broaden indications in line with the shifting SGLT-2 inhibitor market, which is being reshaped around organ-protective benefits rather than simple blood sugar reduction.

Daewoong is expanding the clinical portfolio of Enblo (generic name: inavoglif lozin), a drug approved as Korea's 36th domestically developed new drug in 2022, to demonstrate efficacy in preventing cardiovascular and renal complications, according to industry sources on Sunday. Enblo is an SGLT-2 inhibitor that lowers blood sugar by blocking glucose reabsorption in the kidneys. A key advantage is that it delivers equivalent efficacy at a dose of just 0.3 mg — one-thirtieth the dose of existing drugs — while improving medication convenience. Cumulative investment in the single product has exceeded 110 billion won ($81 million), an exceptional level in the industry.

Daewoong plans to accelerate indication expansion through additional clinical trials. While Enblo is currently prescribed mainly for diabetes patients, the company is conducting research to extend treatment to patients with impaired renal function.

The most closely watched effort is the ENVELOP Study, a clinical trial involving approximately 2,800 patients in Korea. The study uses a registry-based randomized clinical trial design that leverages real-world clinical data, enabling precise comparison of drug efficacy and safety while reflecting actual treatment settings — an advantage over conventional clinical trials. The study is drawing attention as Korea's first large-scale research directly comparing Enblo's cardiovascular and renal protective effects against global SGLT-2 inhibitors.

Daewoong expects that the domestic patient-based clinical evidence accumulated through this study will serve as a differentiating factor for its homegrown drug in a market dominated by foreign pharmaceutical companies. The company is also pursuing development of a triple combination therapy to secure treatment options covering severe patients as well.

Global diabetes treatment clinical expansion is proceeding in parallel. Enblo is pursuing simultaneous Phase 3 trials in Korea and Indonesia for early combination therapy with metformin, a first-line diabetes drug. The simultaneous Phase 3 trial has been approved in Korea, and an Investigational New Drug (IND) application has been submitted in Indonesia.

If the clinical research succeeds, Daewoong will secure the evidence base to prescribe the drug from the earliest stages of diabetes diagnosis. Industry observers note the significance of directly obtaining local patient data in Southeast Asian markets, which hold substantial growth potential.

"It is rare for a Korean company to invest more than 100 billion won in a single new drug to secure global-level clinical evidence," an industry official said. "Enblo could become a case demonstrating the competitiveness of Korean-developed drugs, given that large-scale clinical trials and global expansion are being pursued simultaneously."

This strategy of securing indications across the full treatment spectrum — from early-stage therapy to severe patients — is interpreted as an effort to achieve competitiveness on par with global SGLT-2 drugs. The SGLT-2 market has in fact moved beyond simple blood sugar control, with cardiovascular and renal complication prevention emerging as a new core competitive factor.

The foundation for global market entry is also expanding. Enblo has completed export contracts and product registrations in 26 countries including Brazil, Mexico and Russia. The company is also preparing market entry in Southeast Asia by securing local patient data.

Industry experts view domestically accumulated clinical data and a stable revenue base as essential for Korean-developed drugs to achieve results in the global market. The strategy of securing prescription evidence based on domestic clinical data and then entering overseas markets — as exemplified by LG Chem's Zemiglo — is considered a key factor in raising the probability of success.

"The core of success for Korean-developed drugs is securing a domestic clinical data and revenue base before expanding to global markets," a Daewoong official said. "Our goal is to enter a total of 50 countries by 2030."